These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10462256)

  • 21. Case history. 2: The use of epoetin alfa before high-dose chemotherapy.
    Mertelsmann R
    Ann Oncol; 1997; 8 Suppl 3():S13. PubMed ID: 9341961
    [No Abstract]   [Full Text] [Related]  

  • 22. Questionable conclusions about epoetin alfa.
    Kruse MW; Lee JJ
    Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355
    [No Abstract]   [Full Text] [Related]  

  • 23. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful recombinant erythropoietin therapy for a developing anemic newborn with hereditary spherocytosis.
    Hosono S; Hosono A; Mugishima H; Nakano Y; Minato M; Okada T; Takahashi S; Harada K
    Pediatr Int; 2006 Apr; 48(2):178-80. PubMed ID: 16635181
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeting anemia with erythropoietin during critical illness.
    Cook D; Crowther M
    N Engl J Med; 2007 Sep; 357(10):1037-9. PubMed ID: 17804850
    [No Abstract]   [Full Text] [Related]  

  • 26. Epoetin dosing and dialysis facility ownership.
    Regidor DL; Kalantar-Zadeh K; Kovesdy CP
    JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
    [No Abstract]   [Full Text] [Related]  

  • 27. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
    Lynch DM; Slaven T
    Clin Drug Investig; 2007; 27(9):661-2. PubMed ID: 17705574
    [No Abstract]   [Full Text] [Related]  

  • 28. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
    Demetri GD; Kris M; Wade J; Degos L; Cella D
    J Clin Oncol; 1998 Oct; 16(10):3412-25. PubMed ID: 9779721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin in patients with ST-segment elevation myocardial infarction.
    Chen Y
    JAMA; 2011 Aug; 306(7):705-6; author reply 706. PubMed ID: 21846847
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinicians adjust to latest ESA recommendations.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(16):1467, 1472, 1474. PubMed ID: 21817075
    [No Abstract]   [Full Text] [Related]  

  • 31. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

  • 32. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
    Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with successful epoetin alfa therapy in premature infants.
    Reiter PD; Rosenberg AA; Valuck RJ
    Ann Pharmacother; 2000 Apr; 34(4):433-9. PubMed ID: 10772426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epoetin alfa. A bloodless approach for the treatment of perioperative anemia.
    Faris PM; Ritter MA
    Clin Orthop Relat Res; 1998 Dec; (357):60-7. PubMed ID: 9917701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
    Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
    Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proceedings of the roundtable of experts in surgery blood management. Vienna, Austria, April 7-9, 1995.
    Semin Hematol; 1996 Apr; 33(2 Suppl 2):1-80. PubMed ID: 8999552
    [No Abstract]   [Full Text] [Related]  

  • 39. Ferric carboxymaltose increases epoetin-α response and prevents iron deficiency before elective orthopaedic surgery.
    Rineau E; Chaudet A; Carlier L; Bizot P; Lasocki S
    Br J Anaesth; 2014 Aug; 113(2):296-8. PubMed ID: 25038162
    [No Abstract]   [Full Text] [Related]  

  • 40. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
    Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
    Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.